Back to results
US 2026/0250388 A1Published application
Tcr molecule targeting kras g12v mutation, cell, and uses thereof
AssigneeBeijing Dcty Biotech Co., Ltd.
InventorsShao WEI, Ping WANG, Xiaorui LI, Kunfu WANG
Life of this patent
Estimating the term…
Abstract
A binding protein contains a binding domain having antigen specificity for an antigen peptide:HLA complex. The binding domain has a T cell receptor (TCR) α-chain variable region and a TCR β-chain variable region. The binding protein and a pharmaceutical composition containing the binding protein can be used for treating cancers associated with the antigen peptide.
Claims23
A binding protein, comprising a binding domain having antigen specificity for an antigen peptide:
- HLA complex, wherein the binding domain comprises a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, wherein:
- the antigen peptide comprises an amino acid sequence of VVGAVGVGK (SEQ ID NO:
- 91);
- the HLA is HLA-A*11:01;
- CDR3 of the α chain variable region comprises the amino acid sequence of SEQ ID NO:
- 65, 5, 15, 25, 35, 45, 55, 75, or 85, or an amino acid sequence having at least 80% identity or 90% identity to the amino acid sequence of SEQ ID NO:
- 65, 5, 15, 25, 35, 45, 55, 75, or 85;
- CDR3 of the β chain variable region comprises the amino acid sequence of SEQ ID NO:
- 70, 10, 20, 30, 40, 50, 60, 70, 80, or 90, or an amino acid sequence having at least 80% identity or 90% identity to the amino acid sequence of SEQ ID NO:
- 70, 10, 20, 30, 40, 50, 60, 80, or 90.
7 more elements
(canceled)
(canceled)
16-22. (canceled)
Dependencies are inferred from the claim text.